1. Home
  2. CCLD vs KZIA Comparison

CCLD vs KZIA Comparison

Compare CCLD & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CareCloud Inc.

CCLD

CareCloud Inc.

HOLD

Current Price

$3.62

Market Cap

114.0M

Sector

Technology

ML Signal

HOLD

Logo Kazia Therapeutics Limited

KZIA

Kazia Therapeutics Limited

HOLD

Current Price

$7.18

Market Cap

93.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCLD
KZIA
Founded
1999
1994
Country
United States
Australia
Employees
3650
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
114.0M
93.2M
IPO Year
N/A
2002

Fundamental Metrics

Financial Performance
Metric
CCLD
KZIA
Price
$3.62
$7.18
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$17.67
AVG Volume (30 Days)
661.0K
123.5K
Earning Date
03-12-2026
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$11.49
N/A
Revenue Next Year
$7.95
N/A
P/E Ratio
$32.04
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.14
$0.64
52 Week High
$4.01
$17.40

Technical Indicators

Market Signals
Indicator
CCLD
KZIA
Relative Strength Index (RSI) 63.97 49.05
Support Level $3.23 $6.44
Resistance Level $3.87 $8.05
Average True Range (ATR) 0.23 0.73
MACD 0.01 -0.08
Stochastic Oscillator 82.50 33.73

Price Performance

Historical Comparison
CCLD
KZIA

About CCLD CareCloud Inc.

CareCloud Inc delivers flexible, tech-enabled solutions for healthcare providers of all sizes and multi-specialties across the U.S. It is a healthcare technology company offering cloud-based solutions that simplify clinical, administrative, and financial workflows for medical practices of all sizes. Its comprehensive suite includes Electronic Health Records (EHRs), Practice Management, Revenue Cycle Management (RCM), Medical Billing, Telehealth, and Patient Experience solutions. The group helps practices increase efficiency, improve patient care, and drive sustainable growth-all while ensuring HIPAA compliance and seamless integration. The operating segments of the group are Healthcare IT, which is the key revenue-generating segment, and Medical Practice Management.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Share on Social Networks: